Evolution of Neuroimaging Findings in Severe COVID-19 Patients with Initial Neurological Impairment: An Observational Study.
COVID-19
follow-up
neuroimaging
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
received:
23
03
2022
revised:
26
04
2022
accepted:
26
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Cerebral complications related to the COVID-19 were documented by brain MRIs during the acute phase. The purpose of the present study was to describe the evolution of these neuroimaging findings (MRI and FDG-PET/CT) and describe the neurocognitive outcomes of these patients. During the first wave of the COVID-19 outbreak between 1 March and 31 May 2020, 112 consecutive COVID-19 patients with neurologic manifestations underwent a brain MRI at Strasbourg University hospitals. After recovery, during follow-up, of these 112 patients, 31 (initially hospitalized in intensive care units) underwent additional imaging studies (at least one brain MRI). Twenty-three men (74%) and eight women (26%) with a mean age of 61 years (range: 18-79) were included. Leptomeningeal enhancement, diffuse brain microhemorrhages, acute ischemic strokes, suspicion of cerebral vasculitis, and acute inflammatory demyelinating lesions were described on the initial brain MRIs. During follow-up, the evolution of the leptomeningeal enhancement was discordant, and the cerebral microhemorrhages were stable. We observed normalization of the vessel walls in all patients suspected of cerebral vasculitis. Four patients (13%) demonstrated new complications during follow-up (ischemic strokes, hypoglossal neuritis, marked increase in the white matter FLAIR hyperintensities with presumed vascular origin, and one suspected case of cerebral vasculitis). Concerning the grey matter volumetry, we observed a loss of volume of 3.2% during an average period of approximately five months. During follow-up, the more frequent FDG-PET/CT findings were hypometabolism in temporal and insular regions. A minority of initially severe COVID-19 patients demonstrated new complications on their brain MRIs during follow-up after recovery.
Sections du résumé
BACKGROUND AND OBJECTIVES
Cerebral complications related to the COVID-19 were documented by brain MRIs during the acute phase. The purpose of the present study was to describe the evolution of these neuroimaging findings (MRI and FDG-PET/CT) and describe the neurocognitive outcomes of these patients.
METHODS
During the first wave of the COVID-19 outbreak between 1 March and 31 May 2020, 112 consecutive COVID-19 patients with neurologic manifestations underwent a brain MRI at Strasbourg University hospitals. After recovery, during follow-up, of these 112 patients, 31 (initially hospitalized in intensive care units) underwent additional imaging studies (at least one brain MRI).
RESULTS
Twenty-three men (74%) and eight women (26%) with a mean age of 61 years (range: 18-79) were included. Leptomeningeal enhancement, diffuse brain microhemorrhages, acute ischemic strokes, suspicion of cerebral vasculitis, and acute inflammatory demyelinating lesions were described on the initial brain MRIs. During follow-up, the evolution of the leptomeningeal enhancement was discordant, and the cerebral microhemorrhages were stable. We observed normalization of the vessel walls in all patients suspected of cerebral vasculitis. Four patients (13%) demonstrated new complications during follow-up (ischemic strokes, hypoglossal neuritis, marked increase in the white matter FLAIR hyperintensities with presumed vascular origin, and one suspected case of cerebral vasculitis). Concerning the grey matter volumetry, we observed a loss of volume of 3.2% during an average period of approximately five months. During follow-up, the more frequent FDG-PET/CT findings were hypometabolism in temporal and insular regions.
CONCLUSION
A minority of initially severe COVID-19 patients demonstrated new complications on their brain MRIs during follow-up after recovery.
Identifiants
pubmed: 35632691
pii: v14050949
doi: 10.3390/v14050949
pmc: PMC9145920
pii:
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Pan Afr Med J. 2021 Jan 13;38:30
pubmed: 33777298
J Neurol. 2021 Aug;268(8):2676-2684
pubmed: 33219827
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Neurol Sci. 2021 May;42(5):1643-1648
pubmed: 33515336
Clin Neuroradiol. 2022 Mar;32(1):287-293
pubmed: 33770199
Clin Nucl Med. 2021 May 1;46(5):413-414
pubmed: 33675593
Neuroimage. 2006 Mar;30(1):1-11
pubmed: 16289929
Brain Commun. 2020 Nov 23;2(2):fcaa205
pubmed: 33376990
BMJ Case Rep. 2016 Oct 19;2016:
pubmed: 27797801
Radiology. 2020 Nov;297(2):E242-E251
pubmed: 32544034
Rev Neurol (Paris). 2021 Jan-Feb;177(1-2):85-92
pubmed: 32753321
AJNR Am J Neuroradiol. 2012 Nov;33(10):1918-24
pubmed: 22790248
Neurology. 2017 Apr 11;88(15):1439-1444
pubmed: 28283598
AJNR Am J Neuroradiol. 2021 Aug;42(8):1410-1414
pubmed: 34016586
Neurology. 2016 Aug 30;87(9 Suppl 2):S38-45
pubmed: 27572859
J Neurol Neurosurg Psychiatry. 2020 Aug 27;:
pubmed: 32855293
Eur J Neurol. 2020 Dec;27(12):2651-2657
pubmed: 32881133
Lancet. 2020 Jun 20;395(10241):e109
pubmed: 32505222
Eur J Radiol. 2020 Dec;133:109393
pubmed: 33161199
Med Hypotheses. 2007;69(6):1179-82
pubmed: 17555884
Neurology. 2020 Sep 29;95(13):e1868-e1882
pubmed: 32680942
Eur J Neurol. 2021 Oct;28(10):3245-3253
pubmed: 33576150
J Neuroradiol. 2021 May;48(3):141-146
pubmed: 33340640
Neuroimage. 2002 Sep;17(1):479-89
pubmed: 12482100
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Crit Care. 2016 Oct 24;20:347
pubmed: 31268434
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
Neuroimage. 2016 Nov 15;142:188-197
pubmed: 27431758
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2543-2557
pubmed: 33452633
Neurology. 2005 Feb 8;64(3):548-50
pubmed: 15699394
Mult Scler. 2005 Apr;11(2):140-5
pubmed: 15794385
AJNR Am J Neuroradiol. 2020 Aug;41(8):1384-1387
pubmed: 32554425
Radiology. 2020 Dec;297(3):E313-E323
pubmed: 32677875
J Infect Dis. 2021 Feb 24;223(4):600-609
pubmed: 33249438
J Nucl Med. 2020 Dec;61(12):1726-1729
pubmed: 32709734